Abstract
On 17 April 2009, novel swine origin influenza A virus (S-OIV) cases appeared within the United States. Most influenza A diagnostic assays currently utilized in local clinical laboratories do not allow definitive subtype determination. Detailed subtype analysis of influenza A positive samples in our laboratory allowed early confirmation of a large outbreak of S-OIV in southeastern Wisconsin (SEW). The initial case of S-OIV in SEW was detected on 28 April 2009. All influenza A samples obtained during the 16 week period prior to 28 April 2009, and the first four weeks of the subsequent epidemic were sub typed. Four different multiplex assays were employed, utilizing real time PCR and end point PCR to fully subtype human and animal influenza viral components. Specific detection of S-OIV was developed within days. Data regarding patient demographics and other concurrently circulating viruses were analyzed. During the first four weeks of the epidemic, 679 of 3726 (18.2%) adults and children tested for influenza A were identified with S-OIV infection. Thirteen patients (0.34%) tested positive for seasonal human subtypes of influenza A during the first two weeks and none in the subsequent 2 weeks of the epidemic. Parainfluenza viruses were the most prevalent seasonal viral agents circulating during the epidemic (of those tested), with detection rates of 12% followed by influenza B and RSV at 1.9% and 0.9% respectively. S-OIV was confirmed on day 2 of instituting subtype testing and within 4 days of report of national cases of S-OIV. Novel surge capacity diagnostic infrastructure exists in many specialty and research laboratories around the world. The capacity for broader influenza A sub typing at the local laboratory level allows timely and accurate detection of novel strains as they emerge in the community, despite the presence of other circulating viruses producing identical illness. This is likely to become increasingly important given the need for appropriate subtype driven anti-viral therapy and the potential shortage of such medications in a large epidemic.
Highlights
Introduction of a Novel SwineOrigin Influenza A (H1N1) Virus into Milwaukee, Wisconsin in 2009Swati Kumar 1,2,4,5, Michael J
The majority of influenza diagnostic assays currently utilized in clinical laboratories in the United States do not allow subtype determination
Males aged 19-49 made up only 6.9% of all swine origin influenza A virus (S-OIV) in males while this age range made up 16.2% of S-OIV in females
Summary
Introduction of a Novel SwineOrigin Influenza A (H1N1) Virus into Milwaukee, Wisconsin in 2009Swati Kumar 1,2,4,5, Michael J. Origin Influenza A (H1N1) Virus into Milwaukee, Wisconsin in 2009. Beginning 17 April 2009, increased numbers of novel swine origin influenza A (H1N1) virus (SOIV) cases began to appear in the United States [1]. As part of a rapid clinical and public health response, the Medical College of Wisconsin [Midwest Respiratory Virus Program (MRVP)] and the two affiliated academic private hospitals Children’s Hospital of Wisconsin (CHW) and Froedtert. Hospital [Dynacare Laboratories (DL)] established full genetic subtyping of all influenza A viruses identified in patient samples sent to the respective clinical laboratories. Detection of novel influenza A viruses of pandemic potential will be critical for minimizing the morbidity and mortality of such infections. The majority of influenza diagnostic assays currently utilized in clinical laboratories in the United States do not allow subtype determination
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.